Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B
暂无分享,去创建一个
Lewis R. Vidler | Stefan Knapp | Susanne Müller | Oleg Fedorov | Catherine Rogers | Martin Philpott | Ludovic Drouin | S. Knapp | O. Fedorov | S. Müller | F. Raynaud | A. Chaikuad | A. Hayes | M. Philpott | S. Hoelder | C. Tallant | L. Vidler | W. Akhtar | Catherine Rogers | Cynthia Tallant | Angela Hayes | Florence Raynaud | Manjuan Liu | Swen Hoelder | Manjuan Liu | Apirat Chaikuad | Octovia Monteiro | S. McGrath | Octovia P. Monteiro | Sally McGrath | Wasim Akhtar | L. Drouin
[1] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[2] Babu Varghese,et al. Intramolecular pi-stacking interaction in a rigid molecular hinge substituted with 1-(pyrenylethynyl) units. , 2007, The Journal of organic chemistry.
[3] William A Weiss,et al. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. , 2007, Nature chemical biology.
[4] G. Längst,et al. NoRC—a novel member of mammalian ISWI‐containing chromatin remodeling machines , 2001, The EMBO journal.
[5] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[6] M. Mackey,et al. High content pharmacophores from molecular fields: a biologically relevant method for comparing and understanding ligands. , 2011, Current computer-aided drug design.
[7] Jay Painter,et al. Electronic Reprint Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion , 2005 .
[8] Stefan Knapp,et al. Bromodomains as therapeutic targets , 2011, Expert Reviews in Molecular Medicine.
[9] S. Knapp,et al. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. , 2011, Molecular bioSystems.
[10] I. Grummt,et al. The structure of NoRC‐associated RNA is crucial for targeting the chromatin remodelling complex NoRC to the nucleolus , 2008, EMBO reports.
[11] A. Gingras,et al. Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.
[12] J. Wildeman,et al. Chemistry of sulfonylmethyl isocyanides. 12. Base-induced cycloaddition of sulfonylmethyl isocyanides to carbon,nitrogen double bonds. Synthesis of 1,5-disubstituted and 1,4,5-trisubstituted imidazoles from aldimines and imidoyl chlorides , 1977 .
[13] P. Evans,et al. Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.
[14] S. Knapp,et al. Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains , 2014, Journal of the American Chemical Society.
[15] I. Grummt,et al. The PHD Finger/Bromodomain of NoRC Interacts with Acetylated Histone H4K16 and Is Sufficient for rDNA Silencing , 2005, Current Biology.
[16] D. Huang,et al. Evaluation of functional groups as acetyl-lysine mimetics for BET bromodomain inhibition , 2014 .
[17] F. Diederich,et al. Aromatic rings in chemical and biological recognition: energetics and structures. , 2011, Angewandte Chemie.
[18] Nathan Brown,et al. Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites , 2012, Journal of medicinal chemistry.
[19] Chris Abell,et al. Targeting Low-Druggability Bromodomains: Fragment Based Screening and Inhibitor Design against the BAZ2B Bromodomain , 2013, Journal of medicinal chemistry.
[20] S. Zukin,et al. Epigenetics , 2009, Alzheimer's & Dementia.
[21] R. Eils,et al. BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence , 2014, Nature Genetics.
[22] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[23] S. Knapp,et al. Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening , 2013, Journal of medicinal chemistry.
[24] S. Knapp,et al. Targeting bromodomains: epigenetic readers of lysine acetylation , 2014, Nature Reviews Drug Discovery.
[25] Owen Johnson,et al. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM , 2011, Acta crystallographica. Section D, Biological crystallography.
[26] S. Korsmeyer,et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.
[27] G. Wider,et al. Measuring protein concentrations by NMR spectroscopy. , 2006, Journal of the American Chemical Society.
[28] Nathan Brown,et al. Fragment-based hit identification: thinking in 3D. , 2013, Drug discovery today.
[29] A. Hofman,et al. Identification of a Sudden Cardiac Death Susceptibility Locus at 2q24.2 through Genome-Wide Association in European Ancestry Individuals , 2011, PLoS genetics.
[30] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[31] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[32] Stefan Knapp,et al. The bromodomain interaction module , 2012, FEBS letters.
[33] J. Nezu,et al. A novel family of bromodomain genes. , 2000, Genomics.